Gilead and Novo Nordisk’s NASH trial meets primary endpoint
Drug combinations tested were found to be well tolerated
Read Moreby Lucy Parsons | Nov 17, 2020 | News | 0
Drug combinations tested were found to be well tolerated
Read Moreby Lucy Parsons | Sep 23, 2020 | News | 0
Study detected Nonalcoholic Fatty Liver Disease and Nonalcoholic steatohepatitis
Read Moreby Selina McKee | Aug 26, 2020 | News | 0
The firms will use Engitix’ extracellular matrix (ECM) discovery platform to develop new therapies for fibrotic liver diseases
Read Moreby Selina McKee | Jul 23, 2020 | News | 0
Development of elafibranor will be discontinued for NASH, with the company now focusing on its future as a treatment for PBC
Read Moreby Anna Smith | Apr 15, 2019 | News | 0
The companies will collaborate for a clinical trial combining compounds from their respective pipelines in NASH.
Read Moreby Selina McKee | Feb 12, 2019 | News | 0
Gilead’s selonsertib has failed to hit a key target in a late-stage study involving patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
Read Moreby Selina McKee | Nov 28, 2018 | News | 0
Roche group Genentech is acquiring San Diego-based biotech Jecure Therapeutics.
Read Moreby Selina McKee | Oct 29, 2018 | News | 0
Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease.
Read Moreby Selina McKee | Apr 10, 2018 | News | 0
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million
Read Moreby Selina McKee | Nov 9, 2017 | News | 0
Boehringer Ingelheim has signed a second deal focused on the development of RNA therapeutics for liver diseases.
Read Moreby Selina McKee | Oct 25, 2017 | News | 0
Gilead has presented promising Phase II results for its experimental NASH drug GS-0976, showing significant reductions in the build up of liver fat and a marker of fibrosis.
Read Moreby Selina McKee | May 4, 2017 | News | 0
Novartis has exercised an option giving it global development and commercialisation rights to an experimental drug being developed by US biotech Conatus for nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479